|
Apply by Aug. 16 for early selection
Medicare Lottery For Advanced Care Has Information
Website With Application Form
June 28, 2004 – Senior citizens and Medicare
beneficiaries with chronic illness can learn more about how to enter the
lottery promising 50,000 winners a free sample of the Medicare program
that will be available to others in 2006 by going to a special page on
the Medicare Website.
Click here to go to the page that includes links to
detailed information and an application form. The applications must be
received by Medicare by Sept. 30, 2004.
Starting
July 6, customer service representatives will be available at
1-866-563-5386, TTY Number: 1-866-536-5387 to answer questions about the
demonstration and assist beneficiaries in obtaining and completing the
application forms. Between now and July 6, beneficiaries who have
questions can call 1-800 MEDICARE. Applications will be accepted for
consideration beginning July 6 through Sept. 30.
Those beneficiaries who are
able to get their applications in by Aug. 16 will be in an “early
selection” process that will give them coverage by Sept. 1.
Applications
will be accepted through Sept.30, at which time another selection
process will be held. As long as the application is received by
Sept.30, all applicants will have an equal chance to get into the
demonstration. If enrollment slots are still available, applications
will continue to be accepted after that date.
The demonstration program, created as part of the
Medicare Modernization Act, will extend Medicare coverage to
prescription medicines that can be self-administered rather than
administered by a health care provider. The demonstration will help up
to 50,000 beneficiaries with serious illnesses who do not have
comprehensive prescription drug coverage today.
Last week the agency
announced this Medicare demonstration program that will save seniors and
persons with disabilities substantial money -- up to 90 percent in some
cases -- on the life-enhancing medicines they take for serious diseases,
including cancer, multiple sclerosis and rheumatoid arthritis.
“This demonstration will provide access and
affordability to life-saving medicines for people fighting serious
diseases,” HHS Secretary Tommy G. Thompson
said. “Through this coverage, seniors will save thousands of
dollars on essential medicines that they can take at home. It will
relieve some of the burden of battling a debilitating disease.”
The initiative, known as the Medicare Replacement
Drug Demonstration, was mandated under Section 641 of the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). As
set by Congress, enrollment in the demonstration will be open to 50,000
people and total spending on the covered drugs will be up to $500
million.
Under this initiative, Medicare will pay for
certain drugs and biologicals that can be taken by the patient at home
and that replace drugs which are currently covered under Medicare Part B
when given in a doctor’s office. In addition, newer, more effective
medications that replace some currently covered oral anti-cancer drugs
will also be covered.
“Covering drugs that you can administer yourself
improves access to high-quality care,” said Mark B. McClellan, M.D.,
Ph.D., administrator of the Centers for Medicare & Medicaid Services
(CMS). “In some cases, by avoiding the need for doctor visits and
intravenous injections, costs and medical complications may be reduced
and access and ease of treatment will increase. And many beneficiaries
will get literally tens of thousands of dollars worth of help in
purchasing these critical medicines right away, ahead of the Medicare
drug benefit in 2006.”
Drugs for treatment of such diseases as rheumatoid
arthritis, multiple sclerosis, pulmonary hypertension and a variety of
cancers will be included in the demonstration. The drugs were selected
based on criteria developed after extensive input from physicians and
other experts. The drugs and the diseases that are covered are listed
below.
Beneficiary cost sharing for these drugs will
mirror the “standard” Medicare Part D prescription drug benefit when it
is implemented in 2006 (participants will not pay the monthly premium in
the demonstration, however). Beneficiaries with limited resources and
incomes of less than 150 percent of the federal poverty level (FPL) will
have even lower cost sharing requirements.
The demonstration will give Medicare beneficiaries
a glimpse of the significant savings coming their way when the Part D
prescription drug benefit is fully implemented in 2006.
Examples of estimated savings over a year include:
·
Patients with Chronic
Myelogenous Lymphoma (a cancer) using Gleevec could save nearly 90
percent or $40,654 annually. Gleevec has an estimated annual cost of
$45,952, but patients in the demo would only pay $5,298.
·
Patients with Multiple sclerosis
could save 75 percent or $12,260 annually off medicines that cost an
estimated $16,298 annually. They would pay only $4,038.
·
Patients with rheumatoid
arthritis could save 75 percent or $11,975 annually off medicines that
cost an estimated $16,000. They would pay only $4,025.
·
And patients with pulmonary
hypertension using Tracleer could save 86 percent or $31,255 off of a
cost that otherwise could reach $36,136. They would pay only $4,881.
Low–income
beneficiaries in the demonstration would save significantly more. Using
the above examples, for those between 135 and 150 percent of the FPL
estimated savings would be: for Gleevec they would pay $638, for MS and
rheumatoid arthritis patients they would pay $628, and for someone
taking Tracleer their annual cost would be $638. For those between 100
and 135 percent of the FPL, they would pay at most $60 per year for any
of the drugs covered in the demonstration program, and seniors below 100
percent of FPL could pay less.
“Seniors are
going to save substantial money on their prescription medicines thanks
to the new drug benefit under Medicare, and this demonstration will give
them a sense of the savings that are on the way,” Secretary Thompson
said. “For seniors currently without drug coverage, this new benefit
will help strengthen their health and their pocketbook. It provides
substantial savings on the out-of-pocket costs they currently pay for
medicines.”
As directed
by Congress in creation of the demonstration, approximately 40 percent
of the funding will be allocated for oral anti-cancer medications. If
more beneficiaries apply than Medicare is able to serve, CMS will select
participants among the cancer and non-cancer groups randomly from the
applications received, on an alternating basis between the two groups.
To be
eligible for the demonstration, a beneficiary must be enrolled in
Medicare Part A and Part B, Medicare must be their primary payer, and
the beneficiary may not have comprehensive drug coverage through other
sources (such as TriCare, Medicaid, or an employer or union sponsored
plan). A beneficiary must also have a signed certification from a doctor
that he or she requires one of the drugs covered under the demonstration
for the indicated disease.
“We intend to
work with our state and local partners, and with patient organizations
and others, to help beneficiaries with these serious diseases find out
about how to take advantage of this program -- and about the additional
help now available to assist with drug costs,” Dr. McClellan said.
CMS is
conducting an Open Door Forum on June 29 with patient advocacy groups,
physician specialty groups, physicians and drug manufacturers so they
can help beneficiaries in applying for the program.
To enroll in
the demonstration program, beneficiaries should complete an application,
get their physician to complete the required form certifying their need
for the covered drug, and submit both forms to CMS’ demonstration
contractor, TrailBlazer Health Enterprises.
Participants
in the demonstration will be able to get their drugs at a local retail
pharmacy or by home delivery through Caremark, Trailblazer’s
subcontractor for administering the drug benefit.
The
demonstration will run through Dec. 31, 2005, at which time all
beneficiaries will be able to enroll in the new Medicare Part D drug
benefit.
Starting
immediately, applications may be downloaded from the CMS Web site at
http://www.cms.hhs.gov/researchers/demos/drugcoveragedemo.asp.
MEDICARE REPLACEMENT DRUG DEMONSTRATION – ANNUAL BENEFICIARY COSTS
|
Disease
|
Compound Name
(Brand Name) |
Estimated Annual Retail Cost (1)
|
Estimated Cost under Standard Cost Sharing (2)
|
Savings
(Percent)
|
Estimated Cost under Low Income Subsidy
(135-150% of FPL)
(3) |
Savings
(Percent)
|
Estimated Cost under Low Income Subsidy
(100-135% of FPL)
(4) |
Savings
(Percent)
|
|
Cutaneous T Cell Lymphoma |
Bexarotene (Targretin) |
$61,320 |
$5,951
|
$55,369
(90%) |
$643
|
$60,677
(99%) |
$60
|
$61,260
(100%) |
|
Gastrointestinal Stromal Tumor |
Imatinib Mesylate (Gleevec) |
$45,952 |
$5,298
|
$40,654
(88%) |
$638
|
$45,314
(99%) |
$60
|
$45,892
(100%) |
|
Chronic Myelogenous Lymphoma |
Imatinib Mesylate (Gleevec) |
$45,952 |
$5,298
|
$40,654
(88%) |
$638
|
$45,314
(99%) |
$60
|
$45,892
(100%) |
|
Anaplastic astrocytoma |
Temozolomide (Temodar) |
$27,878 |
$4,530
|
$23,348
(84%) |
$638
|
$27,240
(98%) |
$60
|
$27,818
(100%) |
|
Epithelial Ovarian Cancer |
Altretamine (Hexalen) |
$25,631 |
$4,434
|
$21,197
(83%) |
$638
|
$24,993
(98%) |
$60
|
$25,571
(100%) |
|
Multiple Myeloma |
Thalidomide (Thalomid) |
$24,098 |
$4,369
|
$19,729
(82%) |
$633
|
$23,465
(97%) |
$60
|
$24,038
(100%) |
|
Lung
Cancer
(non-small cell) |
Gefitinib (Iressa) (5) |
$3,500
|
$1,475
|
$2,025
(58%) |
$489
|
$3,011
(86%) |
$60
|
$3,440
(98%) |
|
Breast
Cancer
Stages 2-4 |
Letrozole (Femara) |
$2,843
|
$917
|
$1,926
(68%) |
$405
|
$2,438
(86%) |
$60
|
$2,783
(98%) |
|
|
Exemestane (Aromasin) |
$2,827
|
$903
|
$1,924
(68%) |
$403
|
$2,424
(86%) |
$60
|
$2,767
(98%) |
|
|
Anastrozole (Arimidex) |
$2,700
|
$795
|
$1,905
(71%) |
$387
|
$2,313
(86%) |
$60
|
$2,640
(98%) |
|
|
Tamoxifen (Nolvadex) |
$1,642
|
$536
|
$1,106
(67%) |
$252
|
$1,390
(85%) |
$60
|
$1,582
(96%) |
|
|
Toremifene (Fareston) |
$1,411
|
$487
|
$924
(65%) |
$222
|
$1,189
(84%) |
$60
|
$1,351
(96%) |
|
NON-CANCER DISEASES |
|
Pulmonary Hypertension |
Bosentan (Tracleer) |
$36,136 |
$4,881
|
$31,255
(86%) |
$638
|
$35,498
(98%) |
$60
|
$36,076
(100%) |
|
CMV
Retinitis |
Valcyte (Valganciclovir) |
$22,911 |
$4,319
|
$18,592
(81%) |
$633
|
$22,278
(97%) |
$60
|
$22,851
(100%) |
|
Hepatitis C |
Pegylated interferon alfa-2a (Pegasys, PEG-Intron)
|
$17,600 |
$4,093
|
$13,507
(77%) |
$633
|
$16,967
(96%) |
$60
|
$17,540
(100%) |
|
Multiple Sclerosis |
Interferon beta-1a (Avonex, Rebif), Interferon beta-1b
(Betaseron)
Glatiramer acetate (Copaxone) |
$16,298 |
$4,038
|
$12,260
(75%) |
$628
|
$15,670
(96%) |
$60
|
$16,238
(100%) |
|
Rheumatoid Arthritis |
Anakinra (Kineret), Adalimumab (Humira),
Etanercept (Enbrel) |
$16,000 |
$4,025
|
$11,975
(75%) |
$628
|
$15,372
(96%) |
$60
|
$15,940
(100%) |
|
Paget’s Disease |
Risedronate (Actonel) |
$2,700
|
$795
|
$1,905
(71%) |
$387
|
$2,313
(86%) |
$60
|
$2,640
(98%) |
|
Secondary Hyperparthyroidism |
Doxercalciferol (Hectoral) |
$2,204
|
$656
|
$1,548
(70%) |
$324
|
$1,880
(85%) |
$60
|
$2,144
(97%) |
|
Paget’s Disease |
Alendronate (Fosamax) |
$940
|
$387
|
$553
(59%) |
$162
|
$778
(83%) |
$60
|
$880
(94%) |
|
Osteoporosis (patient must be homebound) |
Calcitonen-nasal (Miacalcin-nasal) |
$778
|
$353
|
$425
(55%) |
$142
|
$636
(82%) |
$60
|
$718
(92%) |
|
(1)
Estimate based on 100% of Average Wholesale Price (AWP) from
March 2004 Redbook for a typical dosage; Actual retail price
for a beneficiary may be more or less. |
|
(2)
Program cost estimated at 85% of AWP. Retail dispensing fee
of $1.50 not included. |
|
(3)
Reduced deductible and coinsurance if income between 135 and
150 percent of poverty level. |
|
(4)
Flat per-prescription payment if income between 100 and 135
percent of poverty level. |
|
(5)
Cost estimated for 3-month course of treatment.
|
|